7 completed. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
Follow Zika Virus: new trials by email Literature Review of Zika Virus trials Research Report on Zika Virus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184 - Zika Virus | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2024-09-24 | 2026-03-09 |
| Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) ZIKV-SJRP/2016-184 Strain, Experimental: ZIKV-Nicaragua/2016 Strain, Placebo - Zika Virus | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2022-02-16 | 2025-04-11 |
| Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults mRNA-1893, Placebo - Zika Virus | Phase 1 | Completed | ModernaTX, Inc. | 120 | 2019-07-30 | 2024-08-21 |
| Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of placebo via subcutaneous injection (0.5ml)., Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml) - Zika Virus | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2018-07-06 | 2025-08-05 |
| Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults VLA1601, Placebo - Zika Virus, Zika Virus Infection | Phase 1 | Completed | Valneva Austria GmbH | 67 | 2018-02-24 | 2019-07-05 |
| Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001) MV-ZIKA, Placebo - Zika Virus | Phase 1 | Completed | Themis Bioscience GmbH | 48 | 2017-05-03 | 2022-08-18 |
| Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects mRNA-1325, Placebo - Zika Virus | Phase 1 | Completed | ModernaTX, Inc. | 90 | 2016-12-21 | 2024-08-21 |
Arbovirus Infections (7) · Flaviviridae Infections (7) · Flavivirus Infections (7) · Infections (7) · Mosquito-Borne Diseases (7) · RNA Virus Infections (7) · Vector Borne Diseases (7) · Virus Diseases (7)
Plasmalyte A (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · ModernaTX, Inc. (2) · Themis Bioscience GmbH (1) · Valneva Austria GmbH (1)
United States (6) · Austria (1) · Puerto Rico (1)
Anna Durbin, MD (2) · Anna Durbin, M.D. (1) · Katrin Dubischar (1) · Kristen Pierce, MD (1)
2016 (1)